Asia On The Move: Lundbeck China Research Head Leaves For GSK
This article was originally published in PharmAsia News
A plethora of personnel changes is taking place in the pharmaceutical industry around Asia as a new year arrives.
You may also be interested in...
Lilly announced it signed strategic international agreements with four diabetes companies to advance connected solutions and streamline care for people with diabetes in markets outside of the US.
Three firms launched initial public offerings during the first week of May, but Gyroscope postponed its IPO while Jasper, Science 37 and Roivant took the special purpose acquisition corporation route.
The partnership helps close the gap between Nkarta and Fate Therapeutics in terms of the breadth of their pipelines.